Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in Sarcoma
NCT02815995Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in sarcoma (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT02815995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815995.